Media coverage about Simulations Plus (NASDAQ:SLP) has been trending somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Simulations Plus earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the technology company an impact score of 47.1645309811487 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several brokerages have recently weighed in on SLP. BidaskClub raised Simulations Plus from a “sell” rating to a “hold” rating in a report on Saturday, February 3rd. Zacks Investment Research lowered Simulations Plus from a “buy” rating to a “hold” rating in a report on Friday, March 23rd. Finally, ValuEngine raised Simulations Plus from a “hold” rating to a “buy” rating in a report on Monday, April 2nd.
Shares of NASDAQ:SLP opened at $17.85 on Monday. Simulations Plus has a 1-year low of $11.00 and a 1-year high of $18.00. The company has a market cap of $309.27, a PE ratio of 52.50 and a beta of -0.56.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 2nd. Stockholders of record on Wednesday, April 25th will be issued a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a dividend yield of 1.34%. The ex-dividend date is Tuesday, April 24th. Simulations Plus’s payout ratio is presently 70.59%.
In related news, Chairman Walter S. Woltosz sold 18,500 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $16.13, for a total transaction of $298,405.00. Following the completion of the transaction, the chairman now owns 5,482,916 shares in the company, valued at approximately $88,439,435.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 33.45% of the stock is owned by company insiders.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.